loader image
Friday, April 4, 2025
78.2 F
McAllen
We Welcome your Press Release
- Advertisement -

New Alzheimer’s Drug Receives Full FDA Approval

Translate to Spanish or other 102 languages!

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes
The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes

Mega Doctor News

- Advertisement -

CLEVELAND CLINIC – According to the Centers for Disease Control and Prevention (CDC), an estimated 6.5 million Americans are living with Alzheimer’s disease, which does not have a cure.

However, researchers are hopeful about a new medication that was recently approved by the Food and Drug Administration (FDA) for people with early-stage disease.

“When we say Alzheimer’s, it’s a large spectrum, so there are very early stages to very advanced dementia,” said Babak Tousi, MD, neurogeriatrician for Cleveland Clinic. “So, at this point, there are no findings supporting the use of this medication for people with moderate to late-stage dementia. This is for people in the very early stages of the disease.”

- Advertisement -

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain.

Amyloid beta plaque has been linked to Alzheimer’s disease.

Dr. Tousi explained that the medication does not treat symptoms of the disease but rather helps to slow the progression of it.

As far as success rates go, results from an 18-month clinical trial showed participants who received the medication had a 27 percent reduction in amyloid beta plaque.

- Advertisement -

Dr. Tousi said that number may sound small, but he believes it’s a good place to start.

“It seems we have achieved some treatment. We can affect the disease trajectory. It is a small benefit, but it’s still a benefit,” he said. “We can slow it down and I think it’s one of many to come down the road to hopefully target it, so that’s the biggest step for us.”

Documented side effects for the medication included micro-hemorrhages and edema, which is accumulation of fluid in brain tissue.

Editor’s note: Dr. Tousi is a paid scientific advisor for Biogen and Eisai.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Clinics Welcomes Board-Certified Orthopedic Trauma Surgeon Dr. Andrew Merwin

Mega Doctor News Orthopedic injuries caused by physical trauma are one of the major causes...

DHR Health’s Jose Almeda, M.D. Appointed to Chronic Kidney Disease Task Force

Mega Doctor News AUSTIN – Governor Greg Abbott appointed Jose Almeda, M.D., Lauren...

DHR Health Welcomes Dr. Andres Saenz, Neurologist

Mega Doctor News EDINBURG, Texas - DHR Health, one of the largest physician-owned...

DHR Health Statement on Cyber Event and Ongoing Patient Care

Mega Doctor News DHR Health continues to respond to a cyber event that occurred on March 20, 2025. As this is an active investigation, we are limited...
- Advertisement -
×